Screener
ResMed RMD Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by ResMed in its filing.
Tagged under the XBRL concept us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss.
The source filing: ResMed’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 6:19 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000943819-26-000025
| Line item | Nine Months Ended March 31, 2026 | Nine Months Ended March 31, 2025 |
|---|---|---|
| Amortization of right-of-use assets | 32,467 | 26,678 |
| Stock-based compensation costs | 76,890 | 66,910 |
| (Gain) loss attributable to equity method investments (note 5) | (4,722) | (2,375) |
| (Gain) loss on equity investments (note 5) | 16,014 | 7,765 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (59,569) | (71,469) |
| Inventories | 23,946 | (48,032) |
| Prepaid expenses, net deferred income taxes and other current assets | (152,410) | 35,612 |
Item 1. Financial Statements
FAQ
- What is ResMed's net gains (losses) on investments?
- ResMed (RMD) reported net gains (losses) on investments of -$10.13M in Q1 2026.
- How has ResMed's net gains (losses) on investments changed year-over-year?
- ResMed's net gains (losses) on investments decreased by 79.4% year-over-year, from -$5.65M to -$10.13M.
- What is the long-term trend for ResMed's net gains (losses) on investments?
- Over 2 years (2022 to 2025), ResMed's net gains (losses) on investments has grown at a -8.1% compound annual growth rate (CAGR), from -$12.2M to -$10.3M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about ResMed's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude